Testing a new drug for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 85 years old
- Have a diagnosis of early Parkinson's disease (idiopathic)
- Have been taking a steady dose of levodopa by itself for at least 2 months
- Have no Parkinson's-related motor complications (score of 0 on a scale that measures these)
- Have mild to moderate Parkinson's (Hoehn and Yahr stage 1-3, when off medication)
- Be able to swallow capsules whole
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3962681 in two groups: healthy volunteers and people with Parkinson's disease. The goal is to see if the drug is safe and how the body handles it, which may lead to future treatments for Parkinson's.
This study tests a new form of Parkinson's medication given through a pump to see how well it works in everyday life for people in the early stages of advanced Parkinson's. It may help control symptoms and improve daily function.
This study tests an investigational drug called MT101-5 for people with early Parkinson's disease. The goal is to see if it is safe and can help slow the progression of symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.